Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : EntreMed (ENMD) -- Ignore unavailable to you. Want to Upgrade?

To: muddphudd who wrote (420)	5/3/1998 12:11:00 AM
From: John McCarthy	Respond to of 2135

Read Post 19947 on Ligand .... Talks about Sunday New York Times article. You folks are in for a GREAT WEEKEND! I was just lurking. Regards, John McCarthy

To: muddphudd who wrote (420)	5/3/1998 12:12:00 AM
From: marc ultra	Read Replies (2) \| Respond to of 2135

Big article in Sat, May 2 NYTimes discussing angiogenesis inhibitors as potential cure for all cancers. Folkman story discussed specifically and in detail and ENMD mentioned. In todays speculative market could see this causing a pop on Monday even though it's not new nytimes.com You can try that link put doubt it will work

To: muddphudd who wrote (420)	5/3/1998 2:22:00 AM
From: dwight martin	Respond to of 2135

Muddphudd- No, I haven't, but I might next week.

To: muddphudd who wrote (420)	5/3/1998 6:45:00 PM
From: dougjn	Read Replies (2) \| Respond to of 2135

Read the Sun NYTimes article. First I've heard of EntreMed. I'm surprised this thread has not been deluged with postings today. Does anyone have a clear sense of what rights Enmd has in the angiostatin/endostatin experimental therapy? The Times says only that EntreMed is "a company in Rockville, Md., that was formed to make and market angiostatin, endostatin and other weaker drugs than can slow cancer growth." It also says later on that "Dr. John Holaday, Entremed's president and chief executive, said his company was working with the Bristol-Myers Squibb Company to develop angiostatin and had not yet decided on a corporate partner to develop endostatin. The drugs are being made in genetically engineered yeast growing in 20-gallon vats." That was it on Enmd. Is Enmd just producing the stuff in small amounts for research (with Dr. Folkman, or Harvard, or no one having any patent rights), or does Enmd have patent or other rights to it, or the process of making it? Anyone know? Doug